[
  {
    "text": "ARTICLE 2",
    "bbox": [
      625,
      86,
      709,
      96
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "GRANT OF RIGHTS",
    "bbox": [
      589,
      117,
      743,
      129
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "2.1 Grant of Rights to MMT",
    "bbox": [
      181,
      134,
      391,
      144
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "(a) Grant to MMT. Subject to the terms and conditions of this Agreement, SIGA hereby grants to MMT an exclusive right and",
    "bbox": [
      247,
      149,
      1000,
      162
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "license, with the right to grant sublicenses as permitted under Section 2.1(b), under the SIGA Intellectual Property solely to Promote the Product in",
    "bbox": [
      112,
      166,
      1000,
      178
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "the Field in the Territory. The license granted by SIGA to MMT under this Section 2.1(a) will be exclusive even as to SIGA with respect to rights to",
    "bbox": [
      112,
      182,
      1000,
      194
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Promote the Product in the Field in the Territory, except as set forth in Section 2.4 below.",
    "bbox": [
      111,
      198,
      770,
      210
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "(b) Sublicense Rights. Except for the subcontractors appointed by MMT as of the Effective Date as listed on Exhibit A attached.",
    "bbox": [
      247,
      214,
      1000,
      226
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "hereto, MMT may not grant sublicenses of the rights and licenses granted to it in Section 2.1(a) to any Affiliate (including Pfizer or any Affiliate of.",
    "bbox": [
      110,
      229,
      1000,
      242
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Pfizer) or Third Party without the prior written approval of SIGA (such approval not to be unreasonably withheld). Each such subcontractor listed",
    "bbox": [
      112,
      246,
      1000,
      258
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "on Exhibit A attached hereto and any Affiliate or Third Party approved by SIGA as an MMT sublicensee pursuant to this Section 2.1(b) shall be",
    "bbox": [
      111,
      262,
      1000,
      275
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "deemed to be a \"Permitted Sublicensee\" for purposes of this Agreement.",
    "bbox": [
      110,
      277,
      657,
      290
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "(c) Potential New Field. From time to time, MMT may request to expand the Field in a particular country in the Territory because it",
    "bbox": [
      247,
      294,
      1000,
      306
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "believes that there is an opportunity to Promote the Product in such new field (a \"Potential New Field'). MMT shall make such request to SIGA in",
    "bbox": [
      110,
      308,
      1000,
      323
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "writing. SIGA will determine whether to approve such Potential New Field, based upon available information regarding the regulatory environment",
    "bbox": [
      112,
      326,
      1000,
      338
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "in such country for such Potential New Field, and whether SIGA will need to seek Regulatory Approval and Pricing Approval and Reimbursement.",
    "bbox": [
      111,
      341,
      1000,
      354
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Approval. The Parties shall discuss the Potential New Field in good faith and upon the mutual written agreement of the Parties to proceed with a",
    "bbox": [
      113,
      358,
      1000,
      370
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Potential New Field in such country, such Potential New Field shall be deemed hereunder to be an \"Expanded Field\"' for purposes of that country",
    "bbox": [
      110,
      373,
      1000,
      387
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "only in the Territory.",
    "bbox": [
      113,
      390,
      263,
      402
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "2.2 Negative Covenants.",
    "bbox": [
      178,
      406,
      361,
      418
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "outside the scope of the licenses granted to it under Section 2.1.",
    "bbox": [
      113,
      438,
      594,
      450
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "(b) SIGA will not, and will not permit any of its Affiliates or licensees to, Promote the Product in the Field in the Territory, except",
    "bbox": [
      247,
      453,
      1000,
      466
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "as set forth in Section 2.4.",
    "bbox": [
      112,
      470,
      304,
      481
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "2.3 Non-Compete Covenant. During the Term, MMT shall not Commercialize in any manner any Competing Product in the Field in any.",
    "bbox": [
      178,
      484,
      1000,
      499
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "country in the Territory; provided, however, the Parties hereby acknowledge that the restrictions set forth in this Section 2.3 shall not apply to any.",
    "bbox": [
      110,
      500,
      1000,
      516
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Affiliates of MMT (including Pfizer). Furthermore, [***].",
    "bbox": [
      110,
      516,
      535,
      531
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "11",
    "bbox": [
      657,
      546,
      675,
      557
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Source: SIGA TECHNOLOGIES INC, 8-K, 6/3/2019",
    "bbox": [
      133,
      1000,
      528,
      1000
    ],
    "label": 33,
    "category": "Audit Rights"
  }
]